The earnings call reflects a strong performance by Mirum Pharmaceuticals, highlighted by significant revenue growth and positive pipeline developments. While there are challenges such as high operating expenses and variability in international sales, the positive aspects significantly outweigh the negatives.

Company Guidance

On the call, Mirum Pharmaceuticals provided strong guidance for 2025, raising their full-year revenue forecast to between $490 million and $510 million, reflecting anticipated close to 50% top-line growth. This increase is driven by the impressive performance of Livmarli, which contributed significantly with $128 million in total revenue for the second quarter, marking a 64% growth compared to the previous year. The company highlighted the successful expansion in both Alagille syndrome and PFIC markets, with Livmarli's demand exceeding expectations, particularly in PFIC where increased disease awareness and genetic testing are identifying more patients. Internationally, Mirum experienced durable growth, supported by the recent launch in Japan by their partner, Takeda. With Livmarli's potential seen as exceeding $1 billion in revenue, Mirum's strategic focus on commercial execution and pipeline advancement, including pivotal studies like the VISTAS Phase IIb in PSC, sets the stage for an exciting 2026. Furthermore, the company reported financial robustness with cash, cash equivalents, and investments of $322 million, reflecting a $29 million increase from the previous year-end.

Strong Revenue Growth

Mirum Pharmaceuticals reported total revenues of $128 million for Q2 2025, representing a 64% growth over the same quarter last year. The company has raised its full-year guidance for 2025 to $490 million to $510 million, positioning for nearly 50% top-line growth.

Livmarli Performance

Livmarli continues to be a key driver, with strong demand in the U.S. and international markets. The recent U.S. launch of a single tablet per dose formulation adds convenience for patients.

Pipeline Progress

The VISTAS Phase IIb study in primary sclerosing cholangitis is on track, with top-line data expected in Q2 2026. The company is also making progress in the VANTAGE PBC and EXPAND studies, and plans to start a Phase II study of MRM-3379 in Fragile X syndrome by year-end.

Positive Financial Outlook

Mirum is operating cash flow positive and expects to continue this trend for the full year. Cash, cash equivalents, and investments were $322 million as of June 30, a $29 million increase from the end of last year.

International Expansion

Livmarli growth is strong internationally, with a successful launch in Japan through partner Takeda. The international markets contributed $31 million in net product sales in Q2.

Mirum Pharmaceuticals (MIRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MIRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.18 / -	-0.3	―	―	―
Aug 06, 2025	2025 (Q2)	-0.33 / -0.12	-0.52	76.92% (+0.40)	―
May 07, 2025	2025 (Q1)	-0.33 / -0.30	-0.54	44.44% (+0.24)	―
Feb 26, 2025	2024 (Q4)	-0.26 / -0.49	-0.63	22.22% (+0.14)
Nov 12, 2024	2024 (Q3)	-0.45 / -0.30	-0.57	47.37% (+0.27)
Aug 07, 2024	2024 (Q2)	-0.47 / -0.52	-1.94	73.20% (+1.42)	―
May 08, 2024	2024 (Q1)	-0.42 / -0.54	-0.8	32.50% (+0.26)	―
Feb 28, 2024	2023 (Q4)	-0.24 / -0.63	-0.99	36.36% (+0.36)
Nov 02, 2023	2023 (Q3)	-0.63 / -0.57	-1.02	44.12% (+0.45)
Aug 03, 2023	2023 (Q2)	-0.80 / -1.94	-0.84	-130.95% (-1.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MIRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$53.39	$59.82	+12.04%
May 07, 2025	$41.22	$45.24	+9.75%
Feb 26, 2025	$50.52	$46.98	-7.01%
Nov 12, 2024	$41.61	$42.28	+1.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mirum Pharmaceuticals Inc (MIRM) report earnings?

Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Nov 12, 2025, After Close (Confirmed).

What is Mirum Pharmaceuticals Inc (MIRM) earnings time?

Mirum Pharmaceuticals Inc (MIRM) earnings time is at Nov 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MIRM EPS forecast?

MIRM EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing